Welcome to our dedicated page for Accendra Health news (Ticker: ACH), a resource for investors and traders seeking the latest updates and insights on Accendra Health stock.
Accendra Health, Inc. (NYSE: ACH) is described as a nationwide provider of products, technology and services that support health beyond the hospital, focusing on chronic and complex health conditions. The company notes that it connects patients, providers and insurers and highlights support for millions of people each year. News related to Accendra Health often reflects this positioning and its evolution from the former Owens & Minor identity.
One key development disclosed by the company is the completion of the sale of its former Products & Healthcare Services business along with the Owens & Minor brand on December 31, 2025. The company also announced that its common stock would begin trading on the New York Stock Exchange under the new ticker symbol ACH, effective shortly after that transaction. Coverage of such announcements provides insight into Accendra Health’s corporate transformation and current focus.
Investors and observers following ACH news can expect updates on the company’s activities in areas such as diabetes, sleep health, wound care, respiratory care, urology and ostomy, as these are the categories Accendra Health identifies in its portfolio. Company communications may also include statements about its products, technology and services that support home-based care and health beyond the hospital.
This news page aggregates company announcements and related coverage so readers can review how Accendra Health describes its strategy, brand structure and areas of focus over time. For those tracking the transition from the Owens & Minor brand to Accendra Health, this page helps provide context on the company’s current direction and its emphasis on supporting chronic and complex health needs outside traditional hospital settings.
Accendra Health (NYSE: ACH) reported fourth-quarter and full-year 2025 continuing operations results, completing the sale of its Products & Healthcare Services business on December 31, 2025. Full-year revenue was $2.762 billion (+3% vs prior year) with operating cash flow $154 million. The company provided 2026 outlook: revenue $2.55–2.65 billion, adjusted EBITDA $335–355 million, and free cash flow $90–110 million. Cash from the P&HS sale and working-capital improvements increased liquidity; year-end cash and equivalents were $281.99 million. Continuing operations recorded a loss from continuing operations of $102.68 million for 2025. Management emphasized transition, cost controls, and balance sheet optimization.
Accendra Health (NYSE: ACH) will release fourth quarter 2025 financial results on Thursday, February 19, 2026 after NYSE close and will host a conference call at 5:00 p.m. EST the same day.
Dial-in numbers are 1-888-300-2035 (toll-free) and 1-646-517-7437 (toll); conference ID 1058917. A live webcast and later replay are available at the company investor events page: investors.accendra.com/events-and-presentations/.
Accendra Health provides home-based care products and services across diabetes, sleep health, wound care, respiratory care, urology and ostomy under brands Apria and Byram.
Accendra Health (NYSE: ACH) announced that its common stock will begin trading on the New York Stock Exchange under the new ticker ACH effective January 2, 2026, and launched a new corporate website at www.accendrahealth.com. The company also confirmed completion of the sale of its former Products & Healthcare Services business and the Owens & Minor brand on December 31, 2025. The release includes customary Safe Harbor forward-looking language and directs investors to the company’s Form 10-K and subsequent SEC reports for risk factors and additional disclosures.